Navigation Links
Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
Date:5/12/2008

Results show promising neurological recovery in severely-injured, acute

cervical spinal cord injury patients treated with Cethrin

HOPKINTON, Mass., May 12 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its potential to restore motor and sensory function after spinal cord injury, or SCI. The trial enrolled a total of 48 patients of which 37 have reached the final 12 month follow up evaluation. The data for these first 37 patients indicate that at 6 and 12 months after treatment, 38% (5 of 13) of cervical injury patients showed marked recovery of motor and sensory function after treatment as measured by a 2-grade or better improvement in the American Spinal Injury Association, or ASIA, Impairment Scale. Analysis of the data by dose group indicates that Cethrin doses of 1 and 3 mg appear to be the most beneficial for cervical patients with 43% (3 of 7) showing the same 2-grade or better recovery of motor and sensory function.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

"The safety and efficacy observations of the Cethrin trial continue to be encouraging. Many patients have shown a degree of improvement far above the expected outcome," commented Dr. Mark Hurtt, Alseres' Chief Medical Officer. "The interim results of the Phase I/IIa study have helped identify what we believe will be the most effective dose range to carry into our Phase IIb trial later this year."

Based on these results, Alseres intends to move forward with its previ
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
2. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
3. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
4. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
7. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
10. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
11. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... MOUNTAIN VIEW, Calif. , Sept. 3, 2014 ... recently completed phase 2 placebo-controlled trial in pediatric ... a statistically significant increase in head circumference.  Decreased ... the disease. Rett syndrome is ... is usually diagnosed by 24 months of age. ...
(Date:9/2/2014)... , Sept. 2, 2014 Astellas has appointed ... property (IP) in the Americas. Kellerman will report directly ... general counsel at Astellas. In his new role, Kellerman ... with the business and manage the region,s intellectual property ... "I am very pleased to welcome Jim to ...
(Date:9/2/2014)... Reportlinker.com announces that a new market ... Asia-Pacific Infusion Therapy Device Market ... The Asia-Pacific ... pumps, syringe infusion pumps, disposable infusion pumps, IV ... are segmented based on the type of displacement ...
Breaking Medicine Technology:Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome 2Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome 3Leading Intellectual Property Counsel, James Kellerman, Joins Astellas as Vice President 2Asia-Pacific Infusion Therapy Device Market 2Asia-Pacific Infusion Therapy Device Market 3Asia-Pacific Infusion Therapy Device Market 4Asia-Pacific Infusion Therapy Device Market 5Asia-Pacific Infusion Therapy Device Market 6Asia-Pacific Infusion Therapy Device Market 7Asia-Pacific Infusion Therapy Device Market 8Asia-Pacific Infusion Therapy Device Market 9Asia-Pacific Infusion Therapy Device Market 10Asia-Pacific Infusion Therapy Device Market 11Asia-Pacific Infusion Therapy Device Market 12Asia-Pacific Infusion Therapy Device Market 13Asia-Pacific Infusion Therapy Device Market 14
... , , , , , , MUMBAI, India, Dec. ... IN, NSE: SUNPHARMA, BSE: 524715) today announced that Glass, Lewis ... that shareholders of Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF) ... of directors, including all of its nominees for election or ...
... , SUNNYVALE, Calif., Dec. 22 Arrayit Corporation (OTC Bulletin ... announced that the Company has made a technological breakthrough in ... microarrays, which are tiny glass substrates that contain rows and ... diagnostics. The advance allows highly precise printing of as many ...
Cached Medicine Technology:Glass Lewis Advises Taro Shareholders to Hold Taro's Board Accountable for Its Failures 2Glass Lewis Advises Taro Shareholders to Hold Taro's Board Accountable for Its Failures 3Glass Lewis Advises Taro Shareholders to Hold Taro's Board Accountable for Its Failures 4Arrayit Corporation Announces Manufacturing Breakthrough 2Arrayit Corporation Announces Manufacturing Breakthrough 3
(Date:9/2/2014)... (PRWEB) September 03, 2014 Autumn ... Top10BestSEOHosting.com wants to celebrate the new season with ... of research and announced that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... hosting suppliers of 2014. , Since 2002 ... hosting provider, and the company’s reputation for reliability ...
(Date:9/2/2014)... pot might be risky business for women, according ... study is the first to demonstrate sex differences ... , Psychology professor Rebecca Craft showed that, thanks ... least 30 percent more sensitive than males to ... in cannabis. Females also develop tolerance to THC ...
(Date:9/2/2014)... Angeles, CA (PRWEB) September 03, 2014 ... health enthusiasts, bodybuilders, and athletes obtain the latest ... its launch. The site, which focuses mainly on ... dedicated to helping individuals increase their workout capacity ... an article available on Top Creatine Monohydrate, Muscle ...
(Date:9/2/2014)... September 02, 2014 Becker's Healthcare ... Officer and Chief Information Officer Strategy Roundtables on ... , Becker's Hospital Review Chief Executive Officer and ... and health system Chief Executive Officers, Chief Financial ... health system executives through high-quality continuing education, ...
(Date:9/2/2014)... Recently, BambooIndustry.com, an excellent company in the bamboo industry, ... bamboo floors to celebrate the coming of autumn. ... the frequent callers, BambooIndustry.com launched a promotion for its ... woven floors, BambooIndustry.com provides many kinds of wonderful items ... woven floors, click lock floors, wide plank floors and ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3Health News:Creatine Monohydrate Reviews Site TopCreatineMonohydrate.com Announces its Launch 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 3Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 4Health News:Cheap Strand Woven Bamboo Floors For Autumn On Sale At BambooIndustry.com 2
... Inc. (Nasdaq: MEDQ ), the largest Medical Transcription ... the positive resolution of several material legal matters , ... Investigation , , As ... documents from the United States Department of Justice ("DOJ") on ...
... College of Surgeons (ACS) today recognized the Institute of Medicine ... was released on December 2, 2008, by the IOM Committee ... to Improve Patient Safety. , ... conclusion that further reductions in the mandated 80-hour work week ...
... YORK, Dec. 3, 2008 Forest Laboratories, Inc. (NYSE: ... of an unsolicited mini-tender offer by TRC Capital Corporation (TRC) ... has received a copy of the tender offer to purchase ... stock, which represents less than 1 per cent of its ...
... MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced ... "Adapting Specialty Pharma Strategy,To Market Conditions" at the 2008 ... at 10:00 am (ET) in New York City. , ... of the panel discussion will be available on the ...
... outperform animal and human derived serum in CHO cell culture. ... ... Cellastim has proven to be a robust replacement for serum derived ... and productivity of CHO cell lines across a variety of chemically ...
... N.J., Dec. 3 As previously announced, HLTH Corporation (Nasdaq: ... (Nasdaq: WBMD ), will be holding their Annual Meetings ... 10, 2008. , , ... the Internet. To listen to the audio webcast of the meetings, ...
Cached Medicine News:Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 4Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 5Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 6Health News:American College of Surgeons Comments on Institute of Medicine Report on Resident Duty Hours 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 3Health News:InVitria's Cellastim Delivers Superior Results in CHO Cell Culture 2Health News:HLTH Corporation and WebMD to Webcast Annual Meetings of Stockholders 2
...
... The mecA ASR contains primers and a FAM-labeled ... bp region of the mecA gene. In addition, ... and DNA for an internal control sequence. This ... and Texas Red reporter dyes such as the ...
... features the ability to use a separate, ... a pre-loaded nitinol filter with a dual-ended ... fully rapid exchange system, the SpideRX Device ... applications:, Carotid Indication - ,The SpideRX Embolic ...
Pefakit PiCT DxS Diluent for Determination of Total Heparin...
Medicine Products: